Literature DB >> 18546629

Defective apoptosis underlies chemoresistance in ovarian cancer.

Karen M Hajra, Lijun Tan, J Rebecca Liu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18546629     DOI： 10.1007/978-0-387-68969-2_16

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


× No keyword cloud information.
  10 in total

1.  Proteomic analysis of cisplatin resistance in human ovarian cancer using 2-DE method.

Authors:  Fengming Gong; Xingchen Peng; Zhi Zeng; Ming Yu; Yuwei Zhao; Aiping Tong
Journal:  Mol Cell Biochem       Date:  2010-11-16       Impact factor: 3.396

2.  Enhancement of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying MDA-7/IL-24.

Authors:  Yu-mei Wu; Kang-jian Zhang; Xue-tian Yue; Yi-qiang Wang; Yi Yang; Gong-chu Li; Na Li; Yi-gang Wang
Journal:  Acta Pharmacol Sin       Date:  2009-03-09       Impact factor: 6.150

3.  Survival prediction based on inherited gene variation analysis.

Authors:  Mine S Cicek; Matthew J Maurer; Ellen L Goode
Journal:  Methods Mol Biol       Date:  2013

4.  Inherited determinants of ovarian cancer survival.

Authors:  Ellen L Goode; Matthew J Maurer; Thomas A Sellers; Catherine M Phelan; Kimberly R Kalli; Brooke L Fridley; Robert A Vierkant; Sebastian M Armasu; Kristin L White; Gary L Keeney; William A Cliby; David N Rider; Linda E Kelemen; Monica B Jones; Prema P Peethambaram; Johnathan M Lancaster; Janet E Olson; Joellen M Schildkraut; Julie M Cunningham; Lynn C Hartmann
Journal:  Clin Cancer Res       Date:  2010-01-26       Impact factor: 12.531

5.  Adenovirus type 12 E1B 55-kilodalton oncoprotein promotes p53-mediated apoptotic response of ovarian cancer to cisplatin.

Authors:  Junnai Wang; Qinglei Gao; Qiang Li
Journal:  Tumour Biol       Date:  2015-03-29

6.  Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancer.

Authors:  Xi Xia; Quanfu Ma; Xiao Li; Teng Ji; Pingbo Chen; Hongbin Xu; Kezhen Li; Yong Fang; Danhui Weng; Yanjie Weng; Shujie Liao; Zhiqiang Han; Ronghua Liu; Tao Zhu; Shixuan Wang; Gang Xu; Li Meng; Jianfeng Zhou; Ding Ma
Journal:  BMC Cancer       Date:  2011-09-21       Impact factor: 4.430

7.  In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival.

Authors:  E Bicaku; Y Xiong; D C Marchion; H S Chon; X B Stickles; N Chen; P L Judson; A Hakam; J Gonzalez-Bosquet; R M Wenham; S M Apte; W Fulp; C L Cubitt; D-T Chen; J M Lancaster
Journal:  Br J Cancer       Date:  2012-05-17       Impact factor: 7.640

8.  Genome expression analysis by suppression subtractive hybridization identified overexpression of Humanin, a target gene in gastric cancer chemoresistance.

Authors:  Negar Mottaghi-Dastjerdi; Mohammad Soltany-Rezaee-Rad; Zargham Sepehrizadeh; Gholamreza Roshandel; Farzaneh Ebrahimifard; Neda Setayesh
Journal:  Daru       Date:  2014-01-08       Impact factor: 3.117

9.  Assessment of concentrations of sTRAIL ligand and its receptors sTRAIL-R1 and sTRAIL-R2 - markers monitoring the course of the extrinsic pathway of apoptosis induction: potential application in ovarian cancer diagnostics.

Authors:  Aleksandra Mielczarek-Palacz; Justyna Sikora; Zdzisława Kondera-Anasz
Journal:  Arch Med Sci       Date:  2015-11-17       Impact factor: 3.318

10.  HtrA1 expression and the prognosis of high-grade serous ovarian carcinoma: a cohort study using digital analysis.

Authors:  Andréanne Gagné; Bernard Têtu; Michèle Orain; Stéphane Turcotte; Marie Plante; Jean Grégoire; Marie-Claude Renaud; Isabelle Bairati; Dominique Trudel
Journal:  Diagn Pathol       Date:  2018-08-21       Impact factor: 2.644
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.